Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Stephen L. Hauser(University of California, San Francisco), Ludwig Kappos(University Hospital of Basel), Fred Lublin(Icahn School of Medicine at Mount Sinai), Hideki Garren(Io Therapeutics (United States)), Anthony Traboulsee(University of British Columbia), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Nicole Mairon(Roche (Switzerland)), Krzysztof Selmaj(University of Warmia and Mazury in Olsztyn), Shibeshih Belachew(Roche (Switzerland)), Gıancarlo Comı(Casa di Cura Columbus), Paulo Fontoura(Roche (Switzerland)), Kottil Rammohan(Martin College), Hans‐Peter Hartung(The University of Sydney), Douglas L. Arnold(McGill University), Gaëlle Klingelschmitt(Roche (Switzerland)), Jerry S. Wolinsky(The University of Texas Health Science Center at Houston), Amit Bar‐Or(University of Pennsylvania), Gavin Giovannoni(University of British Columbia), Donna Masterman(University of British Columbia), Peter Chin(University of British Columbia), Bernhard Hemmer(Munich Cluster for Systems Neurology)
Cited by 1,972
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k